ArticleCancer immunology, immunotherapy : CII2011
CDR2 antigen and Yo antibodies.
Article in Cancer immunology, immunotherapy : CII, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Paraneoplastic Intracellular Neuropathies: A Narrative Review.Neurology and therapy · 2026Review
- Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome.Breast cancer research : BCR · 2026Article
- Serum Onconeural Antibodies in Dogs and Cats for Early Diagnosis of Cancer.Veterinary medicine (Auckland, N.Z.) · 2025Article
- Article
- Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- MicroRNA 452 regulates ASB8, NOL8, and CDR2 expression in colorectal cancer cells.Genes & genomics · 2021Article
- Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.Annals of clinical and translational neurology · 2020Article
- Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.Frontiers in immunology · 2020Review
- Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.Neuropathology and applied neurobiology · 2019Article
- Paraneoplastic cerebellar degeneration with bilateral facial palsy: a rare primary presentation of breast cancer.BMJ case reports · 2018Article
- Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.Cancer biomarkers : section A of Disease markers · 2017Article
- Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.Cancer immunology, immunotherapy : CII · 2017Article
- Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.Journal of neuroimmunology · 2016Article
- 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.Journal of neuroinflammation · 2015Review
- Paraneoplastic neurological syndromes associated with ovarian tumors.Journal of cancer research and clinical oncology · 2015Review
- Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.Acta neuropathologica · 2014Article
- Article
- Cell-mediated immune responses in paraneoplastic neurological syndromes.Clinical & developmental immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic cerebellar degeneration (PCD) is often associated with Yo antibodies that are directed against human cerebellar degeneration-related protein 2 (CDR2). Such antibodies may also be found in ovarian cancer patients without PCD. We studied if there was an association between Yo antibody production and differences in CDR2 cDNA sequence, mRNA or CDR2 expression in ovarian cancers. We found similar CDR2 cDNA sequence, mRNA and protein levels in primary ovarian cancers, with or without associated Yo antibodies. CDR2 was also present in other cancers, as well as in normal ovary tissue. The results suggest that Yo antibodies are not only related to the expression of CDR2 alone, but also to immune dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.